Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,989 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer Disease Dementia Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Person-Environment Fit for Persons With Dementia

NCT05722743
View directory record Official record
Conditions
Dementia Alzheimers, Alzheimer Disease
Interventions
Harmony at HOME, National Institute on Aging Program
Behavioral
Lead sponsor
Elizabeth K Rhodus
Other
Eligibility
21 Years to 99 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 17, 2026, 9:04 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

NCT05531526
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AR1001, Placebo
Drug
Lead sponsor
AriBio Co., Ltd.
Industry
Eligibility
55 Years to 90 Years
Enrollment
1,535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
75
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 9:04 PM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Neuroimaging Study

NCT03618186
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Tau PET scan
Combination Product
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2030
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Phase 2 Interventional

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease

NCT01254773
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Experimental Bapineuzumab
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 89 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
28
States / cities
Tucson, Arizona • La Habra, California • Lomita, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 17, 2026, 9:04 PM EDT
Completed No phase listed Observational

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

NCT02192554
View directory record Official record
Conditions
Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Not listed
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
28
States / cities
Tuscaloosa, Alabama • Costa Mesa, California • Lakewood, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Not applicable Interventional Results available

Seizure Activity in Alzheimer's Disease

NCT01554683
View directory record Official record
Conditions
Alzheimer's Disease, Seizures
Interventions
Low/High/Placebo Dose Keppra (Levetiracetam)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Phase 1 Interventional

Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease

NCT01716637
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Etanercept, Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Biological · Dietary Supplement
Lead sponsor
Life Extension Foundation Inc.
Other
Eligibility
60 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Coral Springs, Florida • Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Not applicable Interventional

CBT for African Americans With Cognitive Impairment

NCT03384069
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Group-based Cognitive Behavioral Therapy (CBT), Phone-based Cognitive Behavioral Therapy (CBT)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants

NCT04394845
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]GTP1
Diagnostic Test
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Phase 3 Interventional Results available

Hormone and Information Processing Study

NCT00539305
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
University of Washington
Other
Eligibility
60 Years to 90 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

NCT05804383
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BMS-984923, Placebo
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation

NCT01958437
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Transcranial direct current stimulation (tDCS)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 88 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
Decatur, Georgia • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Care Coordination System for People With Dementia

NCT04308512
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Dementia Alzheimers
Interventions
Active Nili device, Passive Nili system
Behavioral
Lead sponsor
Bijan Najafi, PhD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 17, 2026, 9:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

NCT07651319
View directory record Official record
Conditions
Alzheimer Dementia (AD)
Interventions
IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 86 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 17, 2026, 9:04 PM EDT
Recruiting Not applicable Interventional

Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)

NCT05205980
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Perturbation training
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
65 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Valdosta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Nicotinamide to Treat Alzheimer's Disease

NCT00580931
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Nicotinamide, Enduramide placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 17, 2026, 9:04 PM EDT
Recruiting Phase 2 Interventional

Daridorexant to Prevent Post-cardiotomy Delirium

NCT07217912
View directory record Official record
Conditions
Postoperative Cognitive Decline, Postoperative Delirium
Interventions
Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

NCT05644977
View directory record Official record
Conditions
Healthy Participants, Alzheimer's Disease Dementia
Interventions
Emraclidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
11
States / cities
Cypress, California • San Diego, California • Hialeah, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Phase 2 Interventional

Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease

NCT00244322
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY450139 dihydrate, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
La Jolla, California • Indianapolis, Indiana • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2007 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Not applicable Interventional

Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone

NCT00392912
View directory record Official record
Conditions
Alzheimer's Disease, Hypogonadism
Interventions
AndroGel (Solvay Pharmaceuticals)
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
55 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Not applicable Interventional Results available

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

NCT01434667
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
APOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Phase 2Phase 3 Interventional

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

NCT01741194
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AC-1204, Placebo
Drug
Lead sponsor
Cerecin
Industry
Eligibility
66 Years to 90 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 17, 2026, 9:04 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

NCT01466088
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil, AZD3480
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 17, 2026, 9:04 PM EDT